Skip to main content
37°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
21.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
439
Open
21.17
Bid (Size)
8.470 (2)
Ask (Size)
31.80 (1)
Prev. Close
21.17
Today's Range
21.17 - 21.17
52wk Range
18.61 - 47.50
Shares Outstanding
66,344,236
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Celldex Therapeutics to Present at Upcoming Investor Conferences
March 04, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
March 03, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
-17.91%
-17.91%
1 Month
-1.67%
-1.67%
3 Month
-21.62%
-21.62%
6 Month
-49.16%
-49.16%
1 Year
-54.03%
-54.03%
More News
Read More
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
February 28, 2025
Via
Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
January 29, 2025
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
December 20, 2024
Via
Benzinga
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
November 20, 2024
Via
Benzinga
Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
February 27, 2025
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
February 18, 2025
Via
Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
January 08, 2025
Via
Benzinga
Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
December 19, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Analyst Expectations For Celldex Therapeutics's Future
October 28, 2024
Via
Benzinga
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
September 25, 2024
Via
Benzinga
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
November 20, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
November 11, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
October 26, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
September 09, 2024
Via
Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
August 12, 2024
Via
Benzinga
Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024
October 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
September 27, 2024
Via
Benzinga
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024
September 25, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024
September 16, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Celldex Therapeutics to Present at Upcoming Investor Conferences
September 12, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
Via
InvestorPlace
Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
Celldex Therapeutics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
